TBCRC 008: Early change in 18F-FDG uptake on PET predicts response to preoperative systemic therapy in human epidermal growth factor receptor 2-negative primary operable breast cancer

Academic Article

Abstract

  • Epigenetic modifiers, including the histone deacetylase inhibitor vorinostat, may sensitize tumors to chemotherapy and enhance outcomes. We conducted a multicenter randomized phase II neoadjuvant trial of carboplatin and nanoparticle albumin-bound paclitaxel (CP) with vorinostat or placebo in women with stage II/III, human epidermal growth factor receptor 2 (HER2)-negative breast cancer, in which we also examined whether change in maximum standardized uptake values corrected for lean body mass (SULmax) on 18F-FDG PET predicted pathologic complete response (pCR) in breast and axillary lymph nodes.
  • Authors

    Published In

    Digital Object Identifier (doi)

    Author List

  • Connolly RM; Leal JP; Goetz MP; Zhang Z; Zhou XC; Jacobs LK; Mhlanga J; Joo HO; Carpenter J; Storniolo AM
  • Start Page

  • 31
  • End Page

  • 37
  • Volume

  • 56
  • Issue

  • 1